Related Experiment Video

Updated: Sep 23, 2025

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn
11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

6.6K

Efficacy of intravenous propranolol for life-threatening diffuse neonatal hemangiomatosis

Takamichi Ishikawa1, Keigo Seki2, Hiroki Uchiyama1

  • 1Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Pediatric Dermatology
|May 16, 2022
PubMed

Insights

Intravenous propranolol effectively treated a neonate with diffuse hemangiomatosis, resolving airway obstruction, heart failure, and anemia. This case highlights IV propranolol as a critical option for severe infantile hemangioma complications.

Area of Science:

  • Pediatric medicine
  • Dermatology
  • Cardiology

Background:

  • Infantile hemangioma (IH) requires systemic treatment for life-threatening complications.
  • Oral propranolol is the standard first-line therapy for IH.
  • Severe IH can manifest with airway obstruction, heart failure, and anemia.

Observation:

  • A neonate presented with diffuse neonatal hemangiomatosis.
  • The infant experienced airway obstruction from subglottic hemangioma.
  • Hepatic hemangiomas caused heart failure, and gastrointestinal bleeding led to anemia.

Findings:

  • Intravenous propranolol was administered to the infant.
  • Treatment with IV propranolol successfully resolved all critical complications.
  • The infant's airway obstruction, heart failure, and anemia were cured.

Implications:

  • Intravenous propranolol is a viable and successful treatment for severe, diffuse infantile hemangioma.
  • Early intervention with IV propranolol can be life-saving in neonates with critical IH.
  • This case expands treatment options for complex infantile hemangioma cases.

Keywords:
diffuse neonatal hemangiomatosisgastrointestinal bleedinghepatic hemangiomahigh-output congestive heart failureintravenous propranolol

More Related Videos

A Swine Model of Neonatal Asphyxia10:36

A Swine Model of Neonatal Asphyxia

Published on: October 11, 2011

14.5K
Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model05:52

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model

Published on: November 4, 2021

3.1K

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.0K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
679
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
92